CL2015002724A1 - Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 - Google Patents

Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23

Info

Publication number
CL2015002724A1
CL2015002724A1 CL2015002724A CL2015002724A CL2015002724A1 CL 2015002724 A1 CL2015002724 A1 CL 2015002724A1 CL 2015002724 A CL2015002724 A CL 2015002724A CL 2015002724 A CL2015002724 A CL 2015002724A CL 2015002724 A1 CL2015002724 A1 CL 2015002724A1
Authority
CL
Chile
Prior art keywords
antibody
disease
methods
treat crohn
crohn
Prior art date
Application number
CL2015002724A
Other languages
English (en)
Inventor
Wei-Jian Pan
Wayne Tsuji
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2015002724A1 publication Critical patent/CL2015002724A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

USO DE ANTICUERPO ANTI-IL-23 PARA TRATAR ENFERMEDAD DE CROHN.
CL2015002724A 2013-03-15 2015-09-15 Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 CL2015002724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361789976P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002724A1 true CL2015002724A1 (es) 2016-03-28

Family

ID=50236361

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002724A CL2015002724A1 (es) 2013-03-15 2015-09-15 Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23

Country Status (17)

Country Link
US (5) US20160031983A1 (es)
EP (2) EP3693007A1 (es)
JP (4) JP2016516686A (es)
KR (1) KR20150128859A (es)
CN (1) CN105307675A (es)
AP (1) AP2015008801A0 (es)
AU (1) AU2014228553B2 (es)
CA (1) CA2906384A1 (es)
CL (1) CL2015002724A1 (es)
EA (1) EA201591579A1 (es)
HK (1) HK1220605A1 (es)
IL (2) IL241343A0 (es)
NZ (1) NZ712294A (es)
PH (1) PH12015502133A1 (es)
SG (2) SG11201507483PA (es)
TN (1) TN2015000402A1 (es)
WO (1) WO2014143540A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778346B2 (en) 2010-11-04 2014-07-15 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
AU2013256724A1 (en) 2012-05-03 2014-10-30 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibodies
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CN113209289A (zh) * 2015-02-26 2021-08-06 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
EP4032906A1 (en) * 2016-10-14 2022-07-27 Boehringer Ingelheim International GmbH Methods of treating diseases
EA202190197A1 (ru) * 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
AU2020332371A1 (en) * 2019-08-21 2022-03-03 Astrazeneca Collaboration Ventures, Llc Use of brazikumab to treat crohn's disease
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
EA013506B1 (ru) 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
EP1931710B1 (en) 2005-08-31 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
US7686047B2 (en) * 2005-11-04 2010-03-30 Roger Cleveland Golf Co., Inc. Golf club cover
HUE034269T2 (en) * 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
PL2426144T3 (pl) 2007-02-23 2019-05-31 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090117289A1 (en) * 2007-10-09 2009-05-07 Enerize Corporation Method and apparatus for deposition of thin film materials for energy storage devices
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP3295957B1 (en) 2010-01-15 2019-08-07 Kirin-Amgen, Inc. Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
EP4137514A1 (en) * 2010-10-08 2023-02-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
US8778346B2 (en) 2010-11-04 2014-07-15 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
EP2661448A4 (en) * 2011-01-07 2015-09-16 Abbvie Inc ANTI-IL-12 / IL-23 ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
AU2014228553A1 (en) 2015-10-08
SG11201507483PA (en) 2015-10-29
EP2968486A1 (en) 2016-01-20
EA201591579A1 (ru) 2016-01-29
EP3693007A1 (en) 2020-08-12
WO2014143540A1 (en) 2014-09-18
IL241343A0 (en) 2015-11-30
JP2016516686A (ja) 2016-06-09
US20180327490A1 (en) 2018-11-15
SG10201805015TA (en) 2018-07-30
JP2020073470A (ja) 2020-05-14
JP2023012516A (ja) 2023-01-25
PH12015502133A1 (en) 2016-01-25
CA2906384A1 (en) 2014-09-18
AP2015008801A0 (en) 2015-10-31
IL275092A (en) 2020-07-30
HK1220605A1 (zh) 2017-05-12
CN105307675A (zh) 2016-02-03
TN2015000402A1 (fr) 2017-01-03
KR20150128859A (ko) 2015-11-18
JP2021107397A (ja) 2021-07-29
AU2014228553B2 (en) 2019-01-24
US20200283517A1 (en) 2020-09-10
US20200017581A1 (en) 2020-01-16
US20160031983A1 (en) 2016-02-04
NZ712294A (en) 2020-04-24
US20170218062A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
AR089993A1 (es) Macrociclos peptidomimeticos
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
UY34406A (es) Compuestos y métodos para mejorar la respuesta inmune innata
BR112015030356A2 (pt) métodos de tratamento de uma taupatia